Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.

Wu CH, Wang Y, Ma M, Mullick AE, Crooke RM, Graham MJ, Daugherty A, Lu HS.

Biosci Rep. 2019 Jan 11;39(1). pii: BSR20180201. doi: 10.1042/BSR20180201. Print 2019 Jan 31. Review.

2.

Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1.

Pirie E, Ray S, Pan C, Fu W, Powers AF, Polikoff D, Miller CM, Kudrna KM, Harris EN, Lusis AJ, Crooke RM, Lee RG.

PLoS Genet. 2018 Oct 29;14(10):e1007732. doi: 10.1371/journal.pgen.1007732. eCollection 2018 Oct.

3.

Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.

Donner AJ, Bell TA, Greenlee S, Graham MJ, Crooke RM.

Nucleic Acid Ther. 2018 Oct;28(5):297-306. doi: 10.1089/nat.2018.0723. Epub 2018 Aug 22.

PMID:
30133341
4.

Antisense oligonucleotides targeting translation inhibitory elements in 5' UTRs can selectively increase protein levels.

Liang XH, Sun H, Shen W, Wang S, Yao J, Migawa MT, Bui HH, Damle SS, Riney S, Graham MJ, Crooke RM, Crooke ST.

Nucleic Acids Res. 2017 Sep 19;45(16):9528-9546. doi: 10.1093/nar/gkx632.

5.

Blood Pressure Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury.

Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP, Crooke RM.

Hypertension. 2017 Sep;70(3):566-576. doi: 10.1161/HYPERTENSIONAHA.117.09755. Epub 2017 Jul 17.

PMID:
28716988
6.

The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue.

Schugar RC, Shih DM, Warrier M, Helsley RN, Burrows A, Ferguson D, Brown AL, Gromovsky AD, Heine M, Chatterjee A, Li L, Li XS, Wang Z, Willard B, Meng Y, Kim H, Che N, Pan C, Lee RG, Crooke RM, Graham MJ, Morton RE, Langefeld CD, Das SK, Rudel LL, Zein N, McCullough AJ, Dasarathy S, Tang WHW, Erokwu BO, Flask CA, Laakso M, Civelek M, Naga Prasad SV, Heeren J, Lusis AJ, Hazen SL, Brown JM.

Cell Rep. 2017 Jul 5;20(1):279. doi: 10.1016/j.celrep.2017.06.053. No abstract available.

7.

The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue.

Schugar RC, Shih DM, Warrier M, Helsley RN, Burrows A, Ferguson D, Brown AL, Gromovsky AD, Heine M, Chatterjee A, Li L, Li XS, Wang Z, Willard B, Meng Y, Kim H, Che N, Pan C, Lee RG, Crooke RM, Graham MJ, Morton RE, Langefeld CD, Das SK, Rudel LL, Zein N, McCullough AJ, Dasarathy S, Tang WHW, Erokwu BO, Flask CA, Laakso M, Civelek M, Naga Prasad SV, Heeren J, Lusis AJ, Hazen SL, Brown JM.

Cell Rep. 2017 Jun 20;19(12):2451-2461. doi: 10.1016/j.celrep.2017.05.077. Erratum in: Cell Rep. 2017 Jul 5;20(1):279.

8.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S.

N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24.

9.

The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis.

Ferguson D, Zhang J, Davis MA, Helsley RN, Vedin LL, Lee RG, Crooke RM, Graham MJ, Allende DS, Parini P, Brown JM.

J Lipid Res. 2017 Feb;58(2):420-432. doi: 10.1194/jlr.M073734. Epub 2016 Dec 10.

10.

Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in liver fatty acid binding protein null mice.

Newberry EP, Xie Y, Kennedy SM, Graham MJ, Crooke RM, Jiang H, Chen A, Ory DS, Davidson NO.

Hepatology. 2017 Mar;65(3):836-852. doi: 10.1002/hep.28941. Epub 2017 Jan 19.

11.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S.

Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21.

PMID:
27665230
12.

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD.

J Clin Invest. 2016 Aug 1;126(8):2855-66. doi: 10.1172/JCI86610. Epub 2016 Jul 11.

13.

Regulation of Hepatic Triacylglycerol Metabolism by CGI-58 Does Not Require ATGL Co-activation.

Lord CC, Ferguson D, Thomas G, Brown AL, Schugar RC, Burrows A, Gromovsky AD, Betters J, Neumann C, Sacks J, Marshall S, Watts R, Schweiger M, Lee RG, Crooke RM, Graham MJ, Lathia JD, Sakaguchi TF, Lehner R, Haemmerle G, Zechner R, Brown JM.

Cell Rep. 2016 Jul 26;16(4):939-949. doi: 10.1016/j.celrep.2016.06.049. Epub 2016 Jul 7.

14.

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM.

Diabetes Care. 2016 Aug;39(8):1408-15. doi: 10.2337/dc16-0126. Epub 2016 Jun 6.

PMID:
27271183
15.

Angiotensinogen Exerts Effects Independent of Angiotensin II.

Lu H, Wu C, Howatt DA, Balakrishnan A, Moorleghen JJ, Chen X, Zhao M, Graham MJ, Mullick AE, Crooke RM, Feldman DL, Cassis LA, Vander Kooi CW, Daugherty A.

Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):256-65. doi: 10.1161/ATVBAHA.115.306740. Epub 2015 Dec 17.

16.

CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation.

Donner AJ, Yeh ST, Hung G, Graham MJ, Crooke RM, Mullick AE.

Mol Ther Nucleic Acids. 2015 Dec 1;4:e265. doi: 10.1038/mtna.2015.40.

17.

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.

Graham MJ, Viney N, Crooke RM, Tsimikas S.

J Lipid Res. 2016 Mar;57(3):340-51. doi: 10.1194/jlr.R052258. Epub 2015 Nov 4. Review. Erratum in: J Lipid Res. 2016 Dec;57(12 ):2235.

18.

Insulin Dissociates the Effects of Liver X Receptor on Lipogenesis, Endoplasmic Reticulum Stress, and Inflammation.

Sun X, Haas ME, Miao J, Mehta A, Graham MJ, Crooke RM, Pais de Barros JP, Wang JG, Aikawa M, Masson D, Biddinger SB.

J Biol Chem. 2016 Jan 15;291(3):1115-22. doi: 10.1074/jbc.M115.668269. Epub 2015 Oct 28.

19.

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD, Kastelein JJ.

N Engl J Med. 2015 Jul 30;373(5):438-47. doi: 10.1056/NEJMoa1400283.

20.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL.

Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.

PMID:
26210642
21.

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.

Miao J, Manthena PV, Haas ME, Ling AV, Shin DJ, Graham MJ, Crooke RM, Liu J, Biddinger SB.

Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1589-96. doi: 10.1161/ATVBAHA.115.305688. Epub 2015 May 28.

22.

Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes.

Åvall K, Ali Y, Leibiger IB, Leibiger B, Moede T, Paschen M, Dicker A, Daré E, Köhler M, Ilegems E, Abdulreda MH, Graham M, Crooke RM, Tay VS, Refai E, Nilsson SK, Jacob S, Selander L, Berggren PO, Juntti-Berggren L.

Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2611-9. doi: 10.1073/pnas.1423849112. Epub 2015 May 4.

23.

Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis.

Miao J, Ling AV, Manthena PV, Gearing ME, Graham MJ, Crooke RM, Croce KJ, Esquejo RM, Clish CB; Morbid Obesity Study Group, Vicent D, Biddinger SB.

Nat Commun. 2015 Apr 7;6:6498. doi: 10.1038/ncomms7498.

24.

The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance.

Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, Marshall S, McDaniel A, Schugar RC, Wang Z, Sacks J, Rong X, Vallim TA, Chou J, Ivanova PT, Myers DS, Brown HA, Lee RG, Crooke RM, Graham MJ, Liu X, Parini P, Tontonoz P, Lusis AJ, Hazen SL, Temel RE, Brown JM.

Cell Rep. 2015 Jan 20;10(3):326-338. doi: 10.1016/j.celrep.2014.12.036. Epub 2015 Jan 15.

25.

Targeting APOC3 in the familial chylomicronemia syndrome.

Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL.

N Engl J Med. 2014 Dec 4;371(23):2200-6. doi: 10.1056/NEJMoa1400284.

26.

Effects of an antisense oligonucleotide inhibitor of C-reactive protein synthesis on the endotoxin challenge response in healthy human male volunteers.

Noveck R, Stroes ES, Flaim JD, Baker BF, Hughes S, Graham MJ, Crooke RM, Ridker PM.

J Am Heart Assoc. 2014 Jul 10;3(4). pii: e001084. doi: 10.1161/JAHA.114.001084.

27.

Acute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion.

Marshall SM, Gromovsky AD, Kelley KL, Davis MA, Wilson MD, Lee RG, Crooke RM, Graham MJ, Rudel LL, Brown JM, Temel RE.

PLoS One. 2014 Jun 5;9(6):e98953. doi: 10.1371/journal.pone.0098953. eCollection 2014.

28.

Effects of antisense oligonucleotides against C-reactive protein on the development of atherosclerosis in WHHL rabbits.

Yu Q, Liu Z, Waqar AB, Ning B, Yang X, Shiomi M, Graham MJ, Crooke RM, Liu E, Dong S, Fan J.

Mediators Inflamm. 2014;2014:979132. doi: 10.1155/2014/979132. Epub 2014 Apr 27.

29.

Inhibiting C-reactive protein for the treatment of cardiovascular disease: promising evidence from rodent models.

Szalai AJ, McCrory MA, Xing D, Hage FG, Miller A, Oparil S, Chen YF, Mazzone M, Early R, Henry SP, Zanardi TA, Graham MJ, Crooke RM.

Mediators Inflamm. 2014;2014:353614. doi: 10.1155/2014/353614. Epub 2014 Apr 2.

30.

Hepatic Mttp deletion reverses gallstone susceptibility in L-Fabp knockout mice.

Xie Y, Fung HY, Newberry EP, Kennedy S, Luo J, Crooke RM, Graham MJ, Davidson NO.

J Lipid Res. 2014 Mar;55(3):540-8. doi: 10.1194/jlr.M046342. Epub 2014 Jan 28.

31.

Reduction of VLDL secretion decreases cholesterol excretion in niemann-pick C1-like 1 hepatic transgenic mice.

Marshall SM, Kelley KL, Davis MA, Wilson MD, McDaniel AL, Lee RG, Crooke RM, Graham MJ, Rudel LL, Brown JM, Temel RE.

PLoS One. 2014 Jan 3;9(1):e84418. doi: 10.1371/journal.pone.0084418. eCollection 2014.

32.

The serine hydrolase ABHD6 Is a critical regulator of the metabolic syndrome.

Thomas G, Betters JL, Lord CC, Brown AL, Marshall S, Ferguson D, Sawyer J, Davis MA, Melchior JT, Blume LC, Howlett AC, Ivanova PT, Milne SB, Myers DS, Mrak I, Leber V, Heier C, Taschler U, Blankman JL, Cravatt BF, Lee RG, Crooke RM, Graham MJ, Zimmermann R, Brown HA, Brown JM.

Cell Rep. 2013 Oct 31;5(2):508-20. doi: 10.1016/j.celrep.2013.08.047. Epub 2013 Oct 3.

33.

Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.

Crooke RM, Graham MJ.

Methods Mol Biol. 2013;1027:309-24. doi: 10.1007/978-1-60327-369-5_14.

PMID:
23912993
34.

Antisense technology: an emerging platform for cardiovascular disease therapeutics.

Lee RG, Crosby J, Baker BF, Graham MJ, Crooke RM.

J Cardiovasc Transl Res. 2013 Dec;6(6):969-80. doi: 10.1007/s12265-013-9495-7. Epub 2013 Jul 16. Review.

35.

Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.

Bell TA 3rd, Graham MJ, Lee RG, Mullick AE, Fu W, Norris D, Crooke RM.

J Lipid Res. 2013 Oct;54(10):2647-57. doi: 10.1194/jlr.M036509. Epub 2013 Jun 25.

36.

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.

Graham MJ, Lee RG, Bell TA 3rd, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J, Baker BF, Burkey J, Crooke ST, Crooke RM.

Circ Res. 2013 May 24;112(11):1479-90. doi: 10.1161/CIRCRESAHA.111.300367. Epub 2013 Mar 29.

PMID:
23542898
37.

Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.

Lee RG, Fu W, Graham MJ, Mullick AE, Sipe D, Gattis D, Bell TA, Booten S, Crooke RM.

J Lipid Res. 2013 Mar;54(3):602-14. doi: 10.1194/jlr.M029215. Epub 2012 Dec 6.

38.

Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice.

Carr RM, Patel RT, Rao V, Dhir R, Graham MJ, Crooke RM, Ahima RS.

Am J Physiol Regul Integr Comp Physiol. 2012 Apr 15;302(8):R996-1003. doi: 10.1152/ajpregu.00177.2011. Epub 2012 Feb 29.

39.

Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -/- mice.

Newberry EP, Kennedy SM, Xie Y, Luo J, Crooke RM, Graham MJ, Fu J, Piomelli D, Davidson NO.

J Lipid Res. 2012 Apr;53(4):744-54. doi: 10.1194/jlr.M020966. Epub 2012 Feb 10.

40.

Endothelial lipase mediates HDL levels in normal and hyperlipidemic rabbits.

Zhang J, Yu Y, Nakamura K, Koike T, Waqar AB, Zhang X, Liu E, Nishijima K, Kitajima S, Shiomi M, Qi Z, Yu J, Graham MJ, Crooke RM, Ishida T, Hirata K, Hurt-Camejo E, Chen YE, Fan J.

J Atheroscler Thromb. 2012;19(3):213-26. Epub 2012 Jan 12.

41.

CGI-58/ABHD5-derived signaling lipids regulate systemic inflammation and insulin action.

Lord CC, Betters JL, Ivanova PT, Milne SB, Myers DS, Madenspacher J, Thomas G, Chung S, Liu M, Davis MA, Lee RG, Crooke RM, Graham MJ, Parks JS, Brasaemle DL, Fessler MB, Brown HA, Brown JM.

Diabetes. 2012 Feb;61(2):355-63. doi: 10.2337/db11-0994. Epub 2012 Jan 6.

42.

Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet.

Li G, Hernandez-Ono A, Crooke RM, Graham MJ, Ginsberg HN.

Metabolism. 2012 Jun;61(6):823-35. doi: 10.1016/j.metabol.2011.11.008. Epub 2011 Dec 29.

43.

A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans.

Jones NR, Pegues MA, McCrory MA, Singleton W, Bethune C, Baker BF, Norris DA, Crooke RM, Graham MJ, Szalai AJ.

Mol Ther Nucleic Acids. 2012 Nov 13;1:e52. doi: 10.1038/mtna.2012.44.

44.

Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis.

Kluve-Beckerman B, Hardwick J, Du L, Benson MD, Monia BP, Watt A, Crooke RM, Mullick A.

Amyloid. 2011 Sep;18(3):136-46. doi: 10.3109/13506129.2011.597464. Epub 2011 Aug 10.

PMID:
21830877
45.

Lowering apolipoprotein CIII delays onset of type 1 diabetes.

Holmberg R, Refai E, Höög A, Crooke RM, Graham M, Olivecrona G, Berggren PO, Juntti-Berggren L.

Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10685-9. doi: 10.1073/pnas.1019553108. Epub 2011 Jun 13.

46.

Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice.

Merki E, Graham M, Taleb A, Leibundgut G, Yang X, Miller ER, Fu W, Mullick AE, Lee R, Willeit P, Crooke RM, Witztum JL, Tsimikas S.

J Am Coll Cardiol. 2011 Apr 12;57(15):1611-21. doi: 10.1016/j.jacc.2010.10.052.

47.

Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism.

Li G, Hernandez-Ono A, Crooke RM, Graham MJ, Ginsberg HN.

J Lipid Res. 2011 May;52(5):971-81. doi: 10.1194/jlr.M013748. Epub 2011 Mar 1.

48.

Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.

Mullick AE, Fu W, Graham MJ, Lee RG, Witchell D, Bell TA, Whipple CP, Crooke RM.

J Lipid Res. 2011 May;52(5):885-96. doi: 10.1194/jlr.M011791. Epub 2011 Feb 22.

49.

Evaluation of an anti-tumor necrosis factor therapeutic in a mouse model of Niemann-Pick C liver disease.

Vincent M, Sayre NL, Graham MJ, Crooke RM, Shealy DJ, Liscum L.

PLoS One. 2010 Sep 23;5(9):e12941. doi: 10.1371/journal.pone.0012941.

50.

Future challenges for microsomal transport protein inhibitors.

Crooke RM.

Curr Vasc Pharmacol. 2010 Sep;8(5):645. No abstract available.

PMID:
20700902

Supplemental Content

Loading ...
Support Center